readthroughSign in
Nov 16, 2026Financing

Surrozen prices $60 million stock offering at $31.67 per share

The Wnt pathway biotech will sell 1,894,540 shares, with closing expected November 16, 2026, and net proceeds earmarked for working capital and R&D.

Surrozen, Inc. entered an underwriting agreement on November 13, 2026 with Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. to sell 1,894,540 shares of common stock at an offering price of $31.67 per share.1 All of the shares are being sold by the company, with gross proceeds expected to be approximately $60 million before underwriting discounts, commissions and other offering expenses.1 The offering is expected to close on November 16, 2026, subject to customary closing conditions.1

The related prospectus supplement puts estimated net proceeds at approximately $55.8 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the company.2 Surrozen said it intends to use the net proceeds for working capital and general corporate purposes, which may include research and development activities, general and administrative matters, and capital expenditures, and may use a portion for strategic investments in complementary businesses, services, products or technologies.2

The deal will leave the company with 13,922,765 shares outstanding after the offering.2 Investors in the offering face an as adjusted net tangible book value of $(20.43) per share after the raise, representing an immediate dilution of $52.10 per share to new investors purchasing shares in the offering.2

The offering was made under Surrozen's effective Form S-3 registration statement, and the company separately noted it had a sales agreement with TD Securities (USA) LLC dated March 23, 2026 allowing sales of up to $50.0 million of common stock, of which $19.4 million remained available as of the date of the prospectus supplement, with the company agreeing not to sell shares under that agreement for 60 days following the offering.2 Surrozen describes itself as a biotechnology company developing product candidates to selectively modulate the Wnt pathway, with its current strategic focus on ophthalmology.2

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.